Zomepirac (Zomax, McNeil Pharmaceutical).
Zomepirac Sodium (Zomax) is a pyrrole-acetic acid structurally related to tolmetin sodium (see Figure 1). Zomepirac is a prostaglandin synthetase inhibitor and is not an opioid, an opioid antagonist, or a salicylate. It is the sodium salt of 5-(4-chlorobenzoyl)-1,4 dimethyl-1H-pyrrole-2-acetate dihydrate. Zomepirac has recently been approved by the Food and Drug Administration for marketing in the United States as an analgesic. It is indicated for all forms of mild to moderately severe pain, and is being promoted as a "comprehensive, non-addicting analgesic."
D000700:Analgesics / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D001702:Biopharmaceutics; D004347:Drug Interactions; D006801:Humans; D007700:Kinetics; D010146:Pain / Q000188:drug therapy; D011758:Pyrroles / Q000494:pharmacology*; D014046:Tolmetin / Q000031:analogs & derivatives / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use
D000700:Analgesics; D011758:Pyrroles; C020549:zomepirac; D014046:Tolmetin